NCT01613053No Longer Available不适用
Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 试验地点
- 1
研究概览
简要总结
Continuation of drug supply in Chinese patients after CAMN107DBR01study termination.
详细描述
Five patients who are on treatment of imatinib and deriving clinical benefit after CAMN107DBR01 study termination and written informed consent obtained will enter the trial, all five patients will receive Glivec (8oomg per day) treatment until tumor progression [by RECIST guidelines, version 1.0], unacceptable toxicity, death or withdrawal of consent.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Five patients who are on treatment of imatinib and deriving clinical benefit after CAMN107DBR01 study termination and written informed consent obtained.
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core StudySarcopeniaNCT02468674Novartis Pharmaceuticals160
已完成
1 期
An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)Mucopolysaccharidosis INCT04453085JCR Pharmaceuticals Co., Ltd.14
已完成
3 期
Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to PlaceboAxial SpondyloarthrithisAnkylosing SpondylitisNCT02505542UCB BIOSCIENCES GmbH736
招募中
3 期
Extension Study in Japanese PV and ET PatientsPolycuthemia Vera and Essential ThrombocythemiaMyeloproliferative nemoplasmsJPRN-jRCT2031200269Kawase Hiroaki67
撤回
2 期
A Phase 2 Extension of Study GCS-100-CS-4003Chronic Kidney DiseaseNCT02333955La Jolla Pharmaceutical Company